 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Immunitor Inc. |
| Street 1: | 365 - 2906 West Broadway |
| Street 2: | |
| City: | Vancouver |
| Province: | |
| Post Code: | |
| Country: | Canada |
| Phone: | 360-566-2194 |
| Email: | info@immunitor.com |
| Web Site: | http://www.immunitor.com |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| Immunitor develops, manufactures, and clinically validates immunotherapies against tuberculosis. Published clinical trials indicate fast sputum clearance resulting from adjunct immunotherapy. Current focus (2011 Q3) is an oral M vaccae formulation in Phase 2b clinical trial. | |
| Total number of staff in your organization: | 6 - 10 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 6 - 10 |
| Number of volunteers who are directly involved with TB: | 6 - 10 |
| What is your organization's annual budget (USD) dedicated to TB? | $100,001-$500,000 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Since our company has a base in Canada, we are considering conduct of a clinical trial among the Inuit people of northern Canada. Our primary geographic focus is on countries where TB is highly prevalent, several of which we are already present with our ongoing work. | |
Geographical Reach | |
| Which country is your headquarters located in: | Canada |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Canada China India Lesotho Mongolia Nigeria Philippines Russian Federation South Africa Thailand Ukraine United States of America |
Specializations | |
|
Provision of TB products |
Specializations in Countries | |
| Provision of TB products | Canada |
| Provision of TB products | China |
| Provision of TB products | India |
| Provision of TB products | Lesotho |
| Provision of TB products | Mongolia |
| Provision of TB products | Nigeria |
| Provision of TB products | Philippines |
| Provision of TB products | Russian Federation |
| Provision of TB products | South Africa |
| Provision of TB products | Thailand |
| Provision of TB products | Ukraine |
| Provision of TB products | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
DOTS Expansion and Enhancement: We are working to enhance DOTS by using assessing the efficacy and safety of adjunct immunotherapies in association with DOTS drugs. Drug-Resistant TB: Our immunotherapies have shown efficacy for drug-resistant TB. TB-HIV: Our immunotherapies have shown efficacy for TB-HIV treatment. New TB Drugs: Although immunotherapies are not usually classed as "drugs", their addition to approved drug combination therapies for TB will affect the necessary duration and mode of treatment. New TB Vaccines: To date, our V5 and V7 products have shown clinical efficacy and safety as treatment vaccines. Current focus is on V7, an oral formulation of M. vaccae. |
|
Declaration | |
| Declaration of interests: Immunitor personnel have stock ownership and are thus incentivized. | |
| Application date: | October 20, 2011 |
| Last updated: | July 12, 2012 |